IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

Compare

622 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

IDYA Analyst Ratings

Strong Buy

15 Buy

2 Hold

0 Sell

Based on 17 analysts giving stock ratings to

IDEAYA

Biosciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

IDYA Stock 12 Month Forecast

Average Price Target

$48.53

▲(42.78% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for IDEAYA Biosciences in the last 3 months. The average price target is $48.53 with a high forecast of $79.00 and a low forecast of $30.00. The average price target represents a 42.78% change from the last price of $33.99.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","80":"$80","29.75":"$29.8","46.5":"$46.5","63.25":"$63.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$79.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,29.75,46.5,63.25,80],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.86,35.48615384615385,39.112307692307695,42.738461538461536,46.364615384615384,49.99076923076923,53.61692307692307,57.24307692307692,60.86923076923077,64.49538461538461,68.12153846153846,71.7476923076923,75.37384615384616,{"y":79,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.86,33.14230769230769,34.424615384615386,35.706923076923076,36.98923076923077,38.27153846153846,39.55384615384615,40.83615384615385,42.11846153846154,43.40076923076923,44.683076923076925,45.965384615384615,47.247692307692304,{"y":48.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,31.86,31.716923076923077,31.573846153846155,31.43076923076923,31.287692307692307,31.144615384615385,31.001538461538463,30.858461538461537,30.715384615384615,30.572307692307692,30.42923076923077,30.286153846153844,30.143076923076922,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.45,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.7,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.35,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.57,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.77,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.12,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.27,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.48,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.86,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$79.00

Average Price Target$48.53

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Graig Suvannavejh

Mizuho Securities

$44→$46

Buy

35.33%

Upside

Reiterated

11/11/25

Mizuho Securities Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)we move our PT to $46 (vs. $44 prior), and with ~50% upside potential, we stay OP-rated on IDYA

Leonid Timashev

RBC Capital

$41

Buy

20.62%

Upside

Reiterated

11/04/25

IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/04/25

IDEAYA Biosciences: Promising Clinical Developments and Strategic Potential Drive Buy Rating

Justin Zelin

BTIG

$62

Buy

82.41%

Upside

Reiterated

11/04/25

IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

Matthew Biegler

Oppenheimer

$36

Buy

5.91%

Upside

Reiterated

11/04/25

Oppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Peter Lawson

Barclays

$40

Buy

17.68%

Upside

Reiterated

11/04/25

IDEAYA Biosciences (IDYA) Gets a Buy from Barclays

Charles Zhu

LifeSci Capital

$62

Buy

82.41%

Upside

Reiterated

11/02/25

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT), IDEAYA Biosciences (NASDAQ: IDYA) and Cardinal Health (NYSE: CAH)

David Dai

UBS

$50

Buy

47.10%

Upside

Reiterated

10/24/25

UBS Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Anupam Rama

J.P. Morgan

$74→$79

Buy

132.42%

Upside

Reiterated

10/23/25

Ideaya Biosciences price target raised to $79 from $74 at JPMorganIdeaya Biosciences price target raised to $79 from $74 at JPMorgan

Paul Jeng

Guggenheim

$50

Buy

47.10%

Upside

Reiterated

10/22/25

Guggenheim Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Andrew Berens

Leerink Partners

$30→$33

Hold

-2.91%

Downside

Reiterated

10/21/25

Leerink Partners Reaffirms Their Hold Rating on IDEAYA Biosciences (IDYA)

Corinne Johnson

Goldman Sachs

$27→$30

Hold

-11.74%

Downside

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)

Yigal Nochomovitz

Citi

$64

Buy

88.29%

Upside

Reiterated

10/19/25

IDEAYA Biosciences: Promising Phase 1/2 Trial Results and Strong Upside Potential Justify Buy RatingWe not only expect IDYA’s Ph3 MUM to deliver favorable PFS by YE25 (~7 months is reasonable based on Ph1/2, >2X tebe, with control around ~3 months) but the new Ph1/2 OS data also support positive Ph3 OS.

Silvan Tuerkcan

Citizens JMP

$45

Buy

32.39%

Upside

Reiterated

10/13/25

Citizens JMP Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)Citizens analyst Silvan Tuerkcan reiterated a Market Outperform rating and $45.00 price target on Ideaya Biosciences (NASDAQ: IDYA).

Eva Fortea Verdejo

Wells Fargo

$44

Buy

29.45%

Upside

Reiterated

09/09/25

Ideaya should be bought on yesterday's selloff, says Wells FargoIdeaya should be bought on yesterday's selloff, says Wells Fargo

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Graig Suvannavejh

Mizuho Securities

$44→$46

Buy

35.33%

Upside

Reiterated

11/11/25

Mizuho Securities Reaffirms Their Buy Rating on IDEAYA Biosciences (IDYA)we move our PT to $46 (vs. $44 prior), and with ~50% upside potential, we stay OP-rated on IDYA

Leonid Timashev

RBC Capital

$41

Buy

20.62%

Upside

Reiterated

11/04/25

IDEAYA Biosciences (IDYA) Receives a Buy from RBC Capital

Tyler Van Buren

TD Cowen

―

Buy

―

Reiterated

11/04/25

IDEAYA Biosciences: Promising Clinical Developments and Strategic Potential Drive Buy Rating

Justin Zelin

BTIG

$62

Buy

82.41%

Upside

Reiterated

11/04/25

IDEAYA Biosciences: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

Matthew Biegler

Oppenheimer

$36

Buy

5.91%

Upside

Reiterated

11/04/25

Oppenheimer Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Peter Lawson

Barclays

$40

Buy

17.68%

Upside

Reiterated

11/04/25

IDEAYA Biosciences (IDYA) Gets a Buy from Barclays

Charles Zhu

LifeSci Capital

$62

Buy

82.41%

Upside

Reiterated

11/02/25

Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (NASDAQ: COGT), IDEAYA Biosciences (NASDAQ: IDYA) and Cardinal Health (NYSE: CAH)

David Dai

UBS

$50

Buy

47.10%

Upside

Reiterated

10/24/25

UBS Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Anupam Rama

J.P. Morgan

$74→$79

Buy

132.42%

Upside

Reiterated

10/23/25

Ideaya Biosciences price target raised to $79 from $74 at JPMorganIdeaya Biosciences price target raised to $79 from $74 at JPMorgan

Paul Jeng

Guggenheim

$50

Buy

47.10%

Upside

Reiterated

10/22/25

Guggenheim Sticks to Their Buy Rating for IDEAYA Biosciences (IDYA)

Andrew Berens

Leerink Partners

$30→$33

Hold

-2.91%

Downside

Reiterated

10/21/25

Leerink Partners Reaffirms Their Hold Rating on IDEAYA Biosciences (IDYA)

Corinne Johnson

Goldman Sachs

$27→$30

Hold

-11.74%

Downside

Reiterated

10/21/25

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT), IDEAYA Biosciences (NASDAQ: IDYA) and Rani Therapeutics Holdings (NASDAQ: RANI)

Yigal Nochomovitz

Citi

$64

Buy

88.29%

Upside

Reiterated

10/19/25

Silvan Tuerkcan

Citizens JMP

$45

Buy

32.39%

Upside

Reiterated

10/13/25

Eva Fortea Verdejo

Wells Fargo

$44

Buy

29.45%

Upside

Reiterated

09/09/25

Ideaya should be bought on yesterday's selloff, says Wells FargoIdeaya should be bought on yesterday's selloff, says Wells Fargo

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering IDEAYA Biosciences

1 Month

xxx

Success Rate

11/17 ratings generated profit

Average Return

+5.16%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 64.71% of your transactions generating a profit, with an average return of +5.16% per trade.

3 Months

xxx

Success Rate

15/22 ratings generated profit

Average Return

+11.48%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +11.48% per trade.

1 Year

Charles ZhuLifeSci Capital

Success Rate

18/22 ratings generated profit

Average Return

+48.10%

reiterated a buy rating 21 days ago

Copying Charles Zhu's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +48.10% per trade.

2 Years

xxx

Success Rate

18/22 ratings generated profit

Average Return

+49.41%

reiterated a xxx

rating 21 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +49.41% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IDYA Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, IDYA has received 45 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. IDYA average Analyst price target in the past 3 months is 48.53.

Each month's total comprises the sum of three months' worth of ratings.

IDYA Financial Forecast

IDYA Earnings Forecast

Next quarter’s earnings estimate for IDYA is -$0.94 with a range of -$1.19 to -$0.70. The previous quarter’s EPS was $1.47. IDYA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.

IDYA Sales Forecast

Next quarter’s sales forecast for IDYA is $6.17M with a range of -$1.60M to $22.20M. The previous quarter’s sales results were $207.83M. IDYA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year IDYA has Performed in-line its overall industry.

IDYA Stock Forecast FAQ

What is IDYA’s average 12-month price target, according to analysts?

Based on analyst ratings, IDEAYA Biosciences’s 12-month average price target is 48.53.

What is IDYA’s upside potential, based on the analysts’ average price target?

IDEAYA Biosciences has 42.78% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is IDYA a Buy, Sell or Hold?

IDEAYA Biosciences has a consensus rating of Strong Buy which is based on 15 buy ratings, 2 hold ratings and 0 sell ratings.

What is IDEAYA Biosciences’s price target?

The average price target for IDEAYA Biosciences is 48.53. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.00 ,the lowest forecast is $30.00. The average price target represents 42.78% Increase from the current price of $33.99.

What do analysts say about IDEAYA Biosciences?

IDEAYA Biosciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of IDYA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

IDYA Analyst Ratings

IDYA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering IDEAYA Biosciences

IDYA Analyst Recommendation Trends

IDYA Financial Forecast

IDYA Earnings Forecast

IDYA Sales Forecast

IDYA Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts